Intra-arterial chemoradiotherapy for locally advanced oral cavity cancer: analysis of therapeutic results in 134 cases

N Fuwa, T Kodaira, K Furutani, H Tchibana, T Nakamura, R Nakahara, T Tomoda, H Inokuchi and T Daimon

1Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan; 2Division of Drug Evaluation & Informatics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

The objective of this study was to investigate the therapeutic results of arterial injection therapy via the superficial temporal artery for 134 cases of stages III and IV (M0) oral cavity cancer retrospectively, and to clarify the prognostic factors. We administered intra-arterial chemoradiotherapy by continuous infusion of carboplatin in 65 cases from January 1993 to July 2002. Systemic chemotherapy was performed on 26 cases at the same time. We administered intra-arterial chemoradiotherapy by cisplatin with sodium thiosulphate in 69 cases from October 2002 to December 2006. Systemic chemotherapy was performed on 48 cases at the same time. The 3-year local control rate was 68.6% (T2-3: 77.9%; T4: 51.3%), and the 3-year survival rate was 53.9% (stage III: 62.9%; stage IV: 45.3%). Regarding the results of multivariate analysis of survival rates, age (<65), selective intra-arterial infusion, and the use of cisplatin as an agent for intra-arterial infusion were significant factors. The therapeutic results of intra-arterial chemoradiotherapy via the superficial temporal artery were not inferior to the results of surgery. In particular, the results of arterial injection therapy by cisplatin with sodium thiosulphate were excellent, so we believe that it will be a new therapy for advanced oral cavity cancer.

Keywords: carcinoma of the oral cavity; intra-arterial chemotherapy; radiation therapy; prognostic factor

As locally advanced oral cavity cancer is difficult to control by radiotherapy, surgery remains the most effective curative therapy (Poulsen et al., 1996). In this case, an extended surgery markedly reduces the quality of life, thus affecting the patient’s social life. Therefore, the development of effective non-resection therapy is extremely important.

In 1992, we started chemoradiation therapy, in which continuous arterial infusion therapy with carboplatin was combined with radiotherapy, by selectively inserting a catheter into the target artery through the superficial temporal artery in patients with locally advanced head and neck cancer (Fuwa et al., 2000). We started therapy in two courses of systemic chemotherapy combined with intra-arterial chemoradiotherapy by continuous intra-arterial infusion of carboplatin and radiation therapy, in an effort to control metastasis in cervical lymph nodes and distant metastasis in 1997 (Fuwa et al., 2007). Furthermore, we changed the agent for intra-arterial infusion from carboplatin to cisplatin in an effort to improve the local control rate in October 2002. This is an improved technique of the Robbins et al. method (Robbins et al., 1994, 2000), whereby an infusion dose of cisplatin was increased by infusing sodium thiosulphate, which is a neutralising agent of cisplatin, from a vein at the time of intra-arterial infusion of cisplatin.

In this article, we analyse the therapeutic results of 134 cases of stages III and IV (M0) oral cavity cancer retrospectively to investigate the prognostic factors, and we inspect the effectiveness of arterial injection therapy via the superficial temporal artery for cases of advanced oral cavity cancer.

MATERIALS AND METHODS

Patient selection criteria

The subjects met the following criteria: (1) the pathology is squamous cell carcinoma; (2) stage III or higher oral cavity cancer (except carcinoma of the base of tongue) without distant metastasis according to the TNM staging published in 2002; (3) patients in whom the performance status (PS) was evaluated as 0–3 according to the classification described by the Eastern Cooperative Oncology Group; (4) ages ranging from 20 to 89 years; (5) the bone marrow function was maintained (leukocyte count: 3000 mm$^{-2}$ or more, platelet count: 100 000 mm$^{-2}$ or more); (6) patients without severe liver, kidney, heart, or lung dysfunction; (7) untreated patients; (8) patients without active double cancer at the start of treatment, and who had not previously undergone radiotherapy in the head and neck region; and (9) patients from whom written informed consent was obtained.

Treatment schedule, administration of the agent

The treatment schedule was divided into four groups (Figure 1). Continuous arterial injection of carboplatin was performed using a portable electrical pump for 6 weeks in Group 1.
Clinical Studies

1040

injection of cisplatin, a cisplatin-neutralising agent, sodium was inserted into the external carotid artery. During the arterial X amount of agent distributed from the findings of the MRI. To distribute the agent appropriately, we decided the cisplatin was established as 20 mg m$^{-2}/C0$ described by Robbins et al.

drip of nedaplatin at 120 mg m$^{-2}$ of continuous intravenous injection of 5-fluorouracil at 700 mg m$^{-2}$ for 5 days (from Day 1 until Day 5) and intravenous drip of cisplatin at 85 mg m$^{-2}$ over 24 h on Day 6. In patients with a poor renal function (24-h creatinine clearance was 60 ml min$^{-1}$ or less), nedaplatin at 100 mg m$^{-2}$ was administered in place of cisplatin.

Radiation therapy

Radiotherapy was performed five times a week by irradiating 1.8–2 Gy of photon beam in a fraction using a 6 MV linear accelerator. The initial irradiation (irradiation method A) was performed five times a week for 4 weeks at a radiation dose of 1.8–2 Gy (total dose: 36–40 Gy). The latter half of irradiation (irradiation method B) was performed five times a week for 3 weeks at a radiation dose of 2 Gy (total dose: 26–30 Gy) (A + B: 66 Gy).

In the irradiation method A, using the bilateral opposing portal irradiation method, 36–40 Gy in 20 fractions was irradiated between the primary lesion, the middle cervical lymph nodes, and a 2 cm safety margin, whereas 36–40 Gy of photon beam was irradiated between the lower cervical region and the supraclavicular fossa using the anterior single irradiation method.

In irradiation method B, an area involving the tumour site on the initial consultation and a 1 cm safety margin was established as the planned target volume (PTV). The radiation dose for the spinal cord was established as 40 Gy or less. In patients with tongue or oral floor cancer in whom brachytherapy was possible, external irradiation at a radiation dose of approximately 50 Gy or less was combined with brachytherapy using a Cs needle or Au grain.

Arterial injection therapy

As previously reported (Fuwa et al., 2000), the anterior ear on the affected side was incised under local anaesthesia to expose the superficial temporal artery. During fluoroscopy, a thin catheter was selectively inserted into the selected artery. When the lesion involved the contralateral side beyond the median line, another catheter was inserted in the contralateral side for bilateral arterial injection. The target artery was the lingual artery in carcinoma of the tongue, the facial artery in carcinomas of the floor of mouth, the buccal mucosa, and lower gingiva, and the maxillary artery in carcinomas of the hard palate and upper gingiva.

When the tumour involved beyond the perfusion area by selected arterial injection, or when severe arteriosclerosis made the selective insertion of a catheter into the selected artery difficult, a catheter was placed in the external carotid artery.

We confirmed that the extent of arterial injection covered the tumour by a pigment, angiography, and MRI from October 2002, in which an extremely low dose of contrast medium for MRI was slowly infused via a catheter for arterial injection.

This clinical trial was approved by the Ethics Committee of Aichi Cancer Center Hospital.

Patient assessments

The treatment response was evaluated based on the MRI. The subjects consulted the outpatient clinic at 1-month intervals for 1 year after the end of treatment, at 2- to 3-month intervals in the second and third years of follow-up, and at 3–5 month intervals after 3 years of follow-up. Follow-up MRI was performed at 4- to 6-month intervals for 2 years after the end of treatment, and at 6- to 8-month intervals thereafter. Chest X-rays were performed at 6- to 8-month intervals, and liver CT or echogram was performed every year until 3 years after the end of treatment.
Regarding the factors that affect the local control rate, we investigated the age (less than 65 years of age vs 65 years of age and over), the T stage (T2, T3 vs T4), the site (tongue vs oral cavity except tongue), the presence of systemic chemotherapy (Groups 1, 3 vs Groups 2, 4), the difference between selective intra-arterial infusion and non-selective intra-arterial infusion (external carotid artery), and the difference between agents for intra-arterial infusion (carboplatin vs cisplatin). Regarding the factors that affect the survival rate, we investigated N stage (NO, 1 vs N2, 3), clinical stage (III vs IV), and PS (0, 1 vs 2, 3) in addition to the six factors noted above.

We used the Kaplan–Meier method for survival and local recurrence-free analyses and the log-rank test to determine whether any significant differences existed between different patients in terms of end points. Survival and local recurrence-free rates were calculated (as of April 1, 2007 or the date of the last medical examination) from the start of treatment to the date of the event.

The Cox regression model was used to perform a multivariate analysis.

RESULTS

Patient population

The subjects consisted of 136 patients with locally advanced oral cavity cancer who underwent intra-arterial chemotherapy combined with radiation therapy between January 1993 and December 2006 (Table 1). Because the amount of agent for intra-arterial infusion in two cases out of 136 was less than 50% of the scheduled amount, we performed an analysis with 134 cases infused with 50% or more of the prescribed amount.

Table 2 shows the TNM staging, age, and PS among the four groups. The median age of Groups 1 and 3 was 17 years older than that of the Groups 2 and 4. The percentage of good PS patients was higher in the Groups 2 and 4. Written informed consent was obtained from all the patients.

Follow-up studies were sufficiently performed in the 131 patients except in three patients as of April 2007. The median follow-up duration for patients who were alive was 45.4 months (range: 5–168 months).

Treatment delivery

The selected arteries consisted of the lingual artery in 52 patients, the bilateral lingual arteries in 12 patients, the facial artery in 12 patients, the faciolingual trunk in 4 patients, the maxillary artery in 3 patients, and the external carotid artery and contralateral lingual artery in 3 patients, and the external carotid artery and contralateral facial artery in 1 patient. During the treatment course, the route was changed from the lingual artery to the external carotid artery in two patients. The total dose of carboplatin ranged from 240 to 800 mg, with a median of 430 mg. The total dose of cisplatin ranged from 40 to 390 mg, with a median of 120 mg. In the arterial injections of carboplatin, 87% of the cases were administered the scheduled quantities of carboplatin, whereas 5% of the cases were administered 50% or less of the scheduled quantities of carboplatin. In the arterial injections of cisplatin, 75% of the cases were administered the scheduled quantities of cisplatin, whereas 5% were administered 50% or less of the scheduled quantities of cisplatin.

Of the patients, 74 (55.2%) patients received systemic chemotherapy. The number of chemotherapy courses was one in 50% or less of the scheduled quantities of cisplatin, whereas 5% were administered in 50% or less of the scheduled quantities of carboplatin. In the arterial injections of cisplatin, 75% of the cases were administered 50% or less of the scheduled quantities of carboplatin.

Table 1 Characteristics of 134 patients with squamous cell carcinoma of the oral cavity

| Age (years) | Median | Range |
|------------|--------|-------|
| Female     | 99     | 65 – 89 |

Gender

| Performance status (ECOG) | 0 | 1 | 2 | 3 |
|---------------------------|---|---|---|---|
| Male                      | 26| 93| 11| 4 |
| Female                    | 45| 67| 49| 2 |

TNM (2002) T stage

| T1 | T2 | T3 | T4a | T4b |
|----|----|----|-----|-----|
| 0  | 16| 67| 49  | 2   |

TNM (2002) N stage

| N0 | N1 | N2a | N2b | N2c | N3 |
|----|----|-----|-----|-----|----|
| 61 | 34 | 1   | 28  | 6   | 4  |

Stage

| III | IV A | IV B |
|-----|------|------|
| 63  | 67   | 4    |

Primary tumour site

| Tongue | Lower gingiva | Floor of the mouth | Buccal mucosa | Upper gingiva | Hard palate |
|--------|--------------|--------------------|---------------|---------------|-------------|
| 88     | 16           | 14                | 12            | 3             | 1           |

Reasons not performing surgery

| Refusal | Old age | Poor performance status | Poor cardio-pulmonary function | Inoperable advanced lesion |
|---------|---------|-------------------------|-------------------------------|---------------------------|
| 78      | 27      | 10                      | 10                            | 9                         |

patients, and interstitial irradiation using Au grain was performed on 27 patients.

Treatment results

A complete response was achieved in 109 patients, and a partial response in 25 patients. A relapse was detected in 65 patients: primary site, 36 patients; cervical lymph node, 19 patients; primary site and cervical lymph node, 2 patients; primary site and distant metastasis, 1 patient; cervical lymph node and distant metastasis, 2 patients; distant metastasis, 5 patients. The 3-year local (primary site) recurrence-free rate of all patients was 68.6% (95% confidence interval (CI): 60.6–77.7%) (Figure 2A). Cumulative local recurrence-free rate of T2-3 and T4 patients at 3 years were 77.9% (95% CI: 69.1–87.9%) and 51.3% (95% CI: 37.5–70.2%), respectively (Figure 2B).

Of the patients demonstrating a relapse, salvage surgery was performed in 15 patients, intra-arterial chemoradiation in 9 patients, intra-arterial chemotherapy in 3 patients, chemoradiation
therapy in 3 patients, radiation therapy in 5 patients, and chemotherapy in 1 patient. Of these 36 patients, 9 patients had successful salvage (surgery in 5 patients, intra-arterial chemo-radiation in 3 patients, chemoradiation therapy in 1 patient), becoming disease-free after the procedure.

At the time of analysis, 65 patients had died, 66 patients were still alive, and 3 patients had been lost to the follow-up. In the 65 patients who had died, the cause of death was oral cavity cancer in 45, other diseases in 18, and treatment-related complication in 2. The 3-year overall survival of all patients was 53.9% (95% CI: 45.4–64.0%) (Figure 3A). Cumulative survival rates of stages III and IV patients at 3 years were 62.9% (95% CI: 51.4–77.0%) and 45.3% (95% CI: 33.9–60.5%), respectively (Figure 3B).

Factors of survival and local recurrence
In a univariate analysis, T factor, the selected artery, and the site were found to have a significant impact on local recurrence, whereas systemic chemotherapy and difference of IA chemotherapy had only a marginal significance. In a multivariate analysis, T factor and difference of IA chemotherapy were of borderline significance (Table 3).

In a univariate analysis, age, systemic chemotherapy, and difference of IA chemotherapy were found to have a significant impact on survival. In a multivariate analysis, age, difference of IA chemotherapy, and selected artery were found to have a significant impact on survival, whereas systemic chemotherapy was not a significant factor (Table 4).

Acute toxicity
Acute toxicity is summarised in Table 5. Grade 3 or higher toxic changes included granulocytopaenia in 60 (45%) patients, thrombopaenia in 31 (23%) patients, anaemia in 26 (19%) patients, and mucositis in 15 (11%) patients. There was no significant difference in the degree of acute toxicity among the four groups.

Table 2 TNM stage, age, and PS among the groups

|                | Group 1 (n = 39) | Group 2 (n = 26) | Group 3 (n = 21) | Group 4 (n = 48) |
|----------------|-----------------|-----------------|-----------------|-----------------|
| Stage          |                 |                 |                 |                 |
| III            | 26              | 14              | 5               | 18              |
| IVA            | 13              | 12              | 14              | 28              |
| IVB            | 0               | 0               | 2               | 2               |
| Age (years)    |                 |                 |                 |                 |
| Median         | 73              | 59              | 77              | 59              |
| Range          | 51–90           | 25–73           | 62–87           | 25–73           |
| PS             |                 |                 |                 |                 |
| 0              | 2               | 8               | 3               | 13              |
| 1              | 29              | 17              | 14              | 33              |
| 2              | 6               | 1               | 3               | 1               |
| 3              | 2               | 0               | 1               | 1               |

Figure 2 Actuarial local (primary site) recurrence-free rate of patients with advanced squamous cell carcinoma of the oral cavity by Kaplan–Meier method. (A) Actuarial local (primary site) recurrence-free rate of all patients. A solid line: local control rate curve. A broken line: 95% CI. (B) Actuarial local (primary site) recurrence-free rate according to the T stage. A solid line: T2 + T3 cases (n = 83). A broken line: T4 cases (n = 51). P = 0.00531.

Figure 3 Actuarial survival rates of patients with advanced squamous cell carcinoma of the oral cavity by Kaplan–Meier method. (A) Actuarial survival rates in all 134 patients. A solid line: overall survival curve. A broken line: 95% CI. (B) Actuarial survival rates according to the stage. A solid line: stage III cases (n = 63). A broken line: stage IV cases (n = 71). P = 0.117.
In addition, no transient or persistent central nervous complications were observed. Treatment-related death was confirmed in two patients. Although tumours in both patients disappeared as a result of therapy, both patients died of gastrointestinal bleeding.

**Chronic toxicity**

We studied chronic toxicity in 97 patients who survived more than 12 months after the treatment. Although these 97 patients did not develop severe problems in their phonation or deglutition function and were able to eat almost normally, continuous glossalgia was recognised in one of the patients and analgesic was sometimes necessary for this patient, and two patients developed osteoradionecrosis, which needed surgery.

**DISCUSSION**

The results of radiotherapy for advanced oral cavity cancer alone were poor (Decroix and Ghossein, 1981; Horiuchi et al, 1982). Currently, surgery is the standard treatment (Poulsen et al, 1996). Several studies have reported arterial injection therapy for oral cavity cancer; however, the number of patients in such studies tended to be small, and its usefulness has not yet been clearly established.
demonstrated (Hirai et al, 1999; Damascelli et al, 2003; Kovacs, 2004). No randomised controlled trials have yet been performed to compare the effectiveness of surgery with chemoradiation, and the usefulness of chemoradiation therapy involving systemic chemotherapy thus remains to be clarified.

After surgery, the 5-year survival rate ranged from 27 to 60% of stage III patients, while it ranged from approximately 12 to 40% of stage IV patients (Chen et al, 1999; Sessions et al, 2002; Greenberg et al, 2003; Lo et al, 2003; Gorysk et al, 2004; Liao et al, 2006; Fan et al, 2007); our results were therefore similar to the results after surgery. In particular, the results of arterial injection therapy by cisplatin with sodium thiosulfate were excellent.

Currently, there are two procedures for performing arterial infusion therapy for head and neck cancer: namely, a procedure in which a catheter is inserted into the target artery through the superficial temporal artery, as presented in this study, and a procedure in which a catheter is inserted into the target artery through the femoral artery by Seldinger’s procedure (Robbins et al, 1994, 2000; Balm et al, 2004; Alkureishi et al, 2006). The latter procedure is simpler than the former procedure, and it facilitates the administration of anticancer agents into several arteries; however, drug administration over a long duration is impossible, and catheter operation-related cranial nerve disorders may sometimes occur. Although Robbins et al reported the incidence of cranial nerve disorders to be 2–4%, no patient showed a cranial nerve disorder in our study. While, in his series, the mean age was 56 years, the median age was 67 years in our study. Therefore, arterial injection therapy in which a catheter is inserted into the target artery through the superficial temporal artery may therefore be appropriate for elderly patients, and the drug can thus be administered over a long duration.

The dose of cisplatin in our study was approximately 1/5 of that described by Robbins et al. However, the duration of administration was 60 times longer. It has been reported that the antitumour effects of cisplatin are correlated with the concentration and duration of administration (DeConti et al, 1973; Drewinko et al, 1973); low-dose cisplatin may exhibit potent antitumour effects.

It remains unclear whether a neutralizer sodium thiosulfate needs to be added to such administered quantities, but we believed that the addition of sodium thiosulfate was necessary, because our study involved elderly patients and patients who have malfunctioning kidneys, and also because the combined usage of systemic chemotherapy was one of the assumptions of the study. Regarding the radiation dosage when arterial injection chemotherapy and radiotherapy were used concomitantly, we administered the same doses as those that we used for cases of combined use of systemic chemotherapy. One of our future tasks is to examine long-term adverse effects, but no severe late-onset effects have been observed thus far.

A randomised controlled trial was performed in the Netherlands, comparing chemoradiation that used cisplatin as a drug agent for arterial injection in a method similar to that of Robbins et al with chemoradiation that used cisplatin as systemic chemotherapy. Unfortunately, the initial outcome showed no difference between the survival rates of the therapies. In the Netherlands study, there were few oral cavity cancer patients (Balm and Rasch, 2006). Although the effectiveness of chemoradiation that concomitantly uses systemic chemotherapy has been clarified for cases of pharyngeal and laryngeal cancer, it has not yet been clarified for cases of oral cavity cancer. Thus, we suggest that randomised controlled trials limit their target cases to, for example, patients with oral cavity cancer.

The results of our study were similar to those of surgery, thus suggesting the usefulness of arterial injection therapy combined with radiation therapy. In particular, the results of arterial injection therapy by cisplatin with sodium thiosulfate were excellent, so we believe that it will be a new therapy for locally advanced oral cavity cancer.

Conflict of interest

The authors state no conflict of interest.

REFERENCES

Alkureishi LW, de Bree R, Ross GL (2006) RADPLAT: an alternative to surgery? Oncologist 11: 469 – 480

Balm AJ, Rasch CR (2006) Results of the Dutch trial IA vs IV chemoradiation in locally advanced head and neck cancer. Abstract of the International Workshop on Intra-Arterial Chemotherapy for Head and Neck Cancer, Chicago, IL.

Balm AJ, Rasch CR, Schornagel JH, Hilgers FJ, Keus RB, Schultz-Kool L, Ackerstaff AH, Busschers W, Tan IB (2004) High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck 26: 485 – 493

Chen YK, Huang HC, Lin LM, Lin CC (1999) Primary oral squamous cell carcinoma: an analysis of 703 cases in southern Taiwan. Oral Oncol 35: 173 – 179

Damascelli B, Patelli GL, Lanocita R, Di Tolla G, Frigerio LF, Marchiano A, Damascelli B, Patelli GL, Lanocita R, Di Tolla G, Frigerio LF, Marchiano A, et al (2006) Three-year experience with superselective intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. Am J Roentgenol 181: 253 – 260

DeConti RC, Tofness BR, Lange CR, Creasey WA (1973) Clinical and pharmacological studies with cis-diaminedichloroplatinum (II). Cancer Res 33: 1310 – 1315

Decroix Y, Ghotsein NA (1981) Experience of the Curie Institute in treatment of cancer of the mobile tongue: I. Treatment policies and result. Cancer 47: 496 – 502

Drewinko B, Brown BW, Gottlieb JA (1975) The effect of cis-diaminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res 35: 3091 – 3095

Fan KH, Lin CY, Kang CJ, Huang SF, Wang HM, Chen EY, Chen IH, Liao CT, Cheng AJ, Chang JT (2007) Combined-modality treatment for advanced oral tongue squamous cell carcinoma. Int J Radiat Oncol Biol Phys 67: 453 – 461

Fuw N, Ito Y, Matsumoto A, Kamata M, Kodaira T, Furutani K, Sasaoka M, Kimura Y, Morita K (2000) A combination therapy of continuous superselective intraarterial carboplatin infusion and radiation therapy for locally advanced head and neck carcinoma. Phase I study. Cancer 89: 2099 – 2105

Fuw N, Kodaira T, Furutani K, Tachibana H, Nakamura T, Daimon T (2007) Chemoradiation therapy using radiotherapy, systemic chemotherapy with 5-fluorouracil and nedaplatin, and intra-arterial infusion using carboplatin for locally advanced head and neck cancer – Phase II study. Oral Oncol 43: 1014 – 1020

Gorsky M, Epstein JB, Oakley C, Le ND, Hay J, Stevenson-Moore P (2004) Carcinoma of the tongue: a case series analysis of clinical presentation, risk factors, staging, and outcome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98: 546 – 552

Greenberg JS, El Naggar AK, Mo V, Roberts D, Myers JN (2003) Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. Implication for therapeutic decision making. Cancer 98: 508 – 515

Hirai T, Korogi Y, Hamatake S, Nishimura R, Baba Y, Takahashi M, Uji Y, Taen A (1999) Stages III and IV squamous cell carcinoma of the mouth: three-year experience with superselective intraarterial chemotherapy using cisplatin prior to definitive treatment. Cardiovasc Intervent Radiol 22: 201 – 205

Horiuchi J, Okuyama T, Shibuya H, Takeda M (1982) Results of brachytherapy for cancer of the tongue with special emphasis on local prognosis. Int J Radiat Oncol Biol Phys 8: 829 – 835

Kovacs AF (2004) Intra-arterial induction high-dose chemotherapy with cisplatin for oral and oropharyngeal cancer: long-term results. Br J Cancer 90(7): 1323 – 1328
Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Kang CJ, Huang SF, Tsai MF, Yen TC (2006) Surgical outcome of T4a and resected T4b oral cavity cancer. *Cancer* 107: 337–344

Lo WL, Kao SY, Chi LY, Wong YK, Chang RC (2003) Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. *J Oral Maxillofac Surg* 61: 751–758

Poulsen M, Aldren C, Tripcony L, Walker Q (1996) Is surgery necessary in stage III and stage IV cancer of head and neck that responds to induction chemotherapy? *Arch Otolaryngol Head Neck Surg* 122: 467–471

Robbins KT, Kumar P, Wong FS, Hartsell WF, Flick P, Palmer R, Weir III AB, Neil HB, Murry T, Ferguson R, Hanchett C, Vieira F, Bush A, Howell SB (2000) Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. *Head Neck* 22: 687–693

Robbins KT, Storniolo AM, Kerber C, Vicario D, Seagren S, Shea M, Hanchett C, Los G, Howell SB (1994) Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. *J Clin Oncol* 12: 2113–2120

Sessions DG, Spector GJ, Lenox J, Haughey B, Chao C, Marks J (2002) Analysis of treatment results for oral tongue cancer. *Laryngoscope* 112: 616–625